

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-6. (cancelled)

7. (currently amended) Fusion A fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises comprising:

a peptide according to claim 1, inhibitor of the translation of proteins, said peptide inhibitor having a length up to 250 amino acids and comprising an amino acid sequence possessing at least 85% identity with the amino acid sequence SEQ ID N° 1; and

an RNA binding protein consisting of MS2CP, wherein said peptide inhibitor being is fused with [[an]] said RNA binding protein, said peptide inhibitor fused with said RNA binding protein is one of SEQ ID N° 5 and SEQ ID N° 6.

8-36. (cancelled)

37. (currently amended) Pharmaceutical A pharmaceutical
composition comprising a fusion polypeptide according to claim 7.

38-40. (cancelled)

41. (new) A fusion polypeptide specifically
inhibiting the translation of a target polynucleotide of
interest, consisting of one of SEQ ID N° 5 and SEQ ID N° 6.

42. (new) A pharmaceutical composition comprising a
fusion polypeptide according to claim 41.